Crohn's Disease: General characteristics and treatment with Adalimumabe biopharmaceutical

Crohn's Disease: General characteristics and treatment with Adalimumabe biopharmaceutical

Show other versions (1)

Crohn's Disease (CD) is a chronic inflammatory disease that affects the gastrointestinal system. The etiology is not fully understood, however, genetic, immunological, microbiological and environmental factors are related to its genesis. The most common manifestations of this disease are diarrh...

Full description

Bibliographic Details
Main Authors:	S. A. Marques, E. E. Oliveira, L. Bizeto, J. L. R. Santos, V. C. G. Soares
Format:	Article
Language:	English
Published:	Universidade Federal de Rondonópolis 2018-02-01
Series:	Scientific Electronic Archives
Subjects:	crohn's disease, risk factors, adalimumab tnf-alfa
Online Access:	https://sea.ufr.edu.br/index.php?journal=SEA&page=article&op=view&path=594

Similar Items

CROHN'S DISEASE: GENERAL CHARACTERISTICS AND TREATMENT WITH ADALIMUMABE BIOPHARMACEUTICAL
by: S. A. Marques, et al.
Published: (2018-02-01)

ADALIMUMAB INDUCTION AND MAINTAINING REMISSION FOR CROHN’S DISEASE IN PATIENT WHO LOST RESPONSE TO INFLIXIMAB. Case report
by: Ivaylo Vazharov, et al.
Published: (2016-12-01)

HEPATITIS AND PNEUMONITIS DURIN ADALIMUMAB THERAPY IN CROHN? DISEASE: mind the histoplasmosis!
by: Bruno do Valle PINHEIRO, et al.
Published: (2014-03-01)

Adalimumab induced psoriasis during the treatment of inflammatory bowel disease – case report
by: Edyta Lelonek, et al.
Published: (2015-09-01)

Administration Timing Is the Best Clinical Outcome Predictor for Adalimumab Administration in Crohn's Disease
by: Mauro Mastronardi, et al.
Published: (2019-11-01)

Efficacy and safety of adalimumab in the treatment of Crohn's disease in children
by: Víctor Manuel Navas-López, et al.
Published: (2013-12-01)

Efficacy of adalimumab for the treatment of extraintestinal manifestations of Crohn's disease Eficacia del adalimumab en el tratamiento de las manifestaciones extraintestinales de la enfermedad de Crohn
by: Manuel Barreiro-de-Acosta, et al.
Published: (2012-09-01)

A real-world study focused on the effectiveness and safety of adalimumab as first-line anti-TNF treatment for paediatric Crohn's disease
by: Víctor Manuel Navas-López, et al.
Published: (2018-02-01)

Adalimumab and azathioprine in the prevention of postoperative crohn’s disease recurrence
by: A. V. Poletova, et al.
Published: (2020-10-01)

Efectividad y seguridad en nuestro entorno de adalimumab como tratamiento anti-TNF de primera linea en niños con enfermedad de Crohn
by: Víctor Manuel Navas-López, et al.
Published: (2018-02-01)

Outcomes of limited period of adalimumab treatment in moderate to severe Crohn's disease patients: Taiwan Society of Inflammatory Bowel Disease Study
by: Wei-Chen Lin, et al.
Published: (2017-10-01)

Behandling med adalimumab vid Crohns sjukdom
by: Reimer Rasmusson, Ida
Published: (2009)

Treatment persistence during therapeutic sequences with adalimumab and infliximab in the treatment of Crohn's disease
by: Carlos Taxonera, et al.

Crohn’s Disease Associated Pyoderma Gangrenosum Treated with Adalimumab
by: Despoina Kakagia, et al.
Published: (2012-03-01)

A HISTORY CASE OF ADALIMUMAB TREATMENT IN A FEMALE PATIENT WITH JUVENILE ARTHRITIS AND UVEITIS AS MANIFESTATIONS OF CROHN’S DISEASE
by: V. A. Malievskii, et al.
Published: (2013-07-01)

Adalimumab behandling vid Crohns sjukdom : erfarenheter av egenvård
by: Forsell, Anette, et al.
Published: (2012)

Listeria Monocytogenes Brain Abscess in Crohn’s Disease Treated with Adalimumab
by: Amporn Atsawarungruangkit, et al.
Published: (2017-11-01)

NOD2, CD14 and TLR4 mutations do not influence response to adalimumab in patients with Crohn's disease: a preliminary report Las mutaciones de NOD2, CD14 y TLR4 no influyen sobre la respuesta al adalimumab en pacientes con enfermedad de Crohn: informe preliminar
by: M. Barreiro-de Acosta, et al.
Published: (2010-10-01)

Adalimumab Dose-Escalation Therapy Is Effective in Refractory Crohn’s Disease Patients with Loss of Response to Adalimumab, Especially in Cases without Previous Infliximab Treatment
by: Taketo Suzuki, et al.
Published: (2019-02-01)

Clinical efficacy of adalimumab versus infliximab and the factors associated with recurrence or aggravation during treatment of anal fistulas in Crohn's disease
by: Cheng-Chun Ji, et al.
Published: (2017-04-01)

Safety and Efficacy of Adalimumab for Patients With Moderate to Severe Crohn's Disease: The Taiwan Society of Inflammatory Bowel Disease (TSIBD) Study
by: Chen-Wang Chang, et al.
Published: (2014-10-01)

SAFETY PROFILE OF ANTI-TNF THERAPY IN CROHN’S DISEASE MANAGEMENT: A BRAZILIAN SINGLE-CENTER DIRECT RETROSPECTIVE COMPARISON BETWEEN INFLIXIMAB AND ADALIMUMAB
by: Mariella BAU, et al.
Published: (2017-09-01)

Adalimumab for endoscopic and histopathological mucosal healing in paediatric patients with moderate to severe Crohn’s disease
by: Edyta Szymanska, et al.
Published: (2016-12-01)

Efficacy of adalimumab in patients with crohn's disease and failure to infliximab therapy: a clinical series Eficacia de Adalimumab en pacientes con enfermedad de Crohn y fracaso previo a la terapia con Infliximab: resultados de una serie clínica
by: Patricia Cordero-Ruiz, et al.
Published: (2011-06-01)

Tratamiento de inducción y mantenimiento con adalimumab en la enfermedad de Crohn: un estudio abierto Adalimumab induction and maintenance therapy from Crohn's diseas: An open-label study
by: N. López Palacios, et al.
Published: (2008-11-01)

Adalimumab induction and maintenance therapy achieve clinical remission and response in Chinese patients with Crohn's disease
by: Kai-Chun Wu, et al.
Published: (2016-04-01)

Efficacy of adalimumab as second-line therapy in a pediatric cohort of Crohn’s disease patients who failed infliximab therapy: the Italian Society of Pediatric Gastroenterology, Hepatology, and Nutrition experience
by: Alvisi P, et al.
Published: (2019-01-01)

Clinical status, quality of life, and work productivity in Crohn's disease patients after one year of treatment with adalimumab
by: Cristina Saro, et al.

Profile of adalimumab and its potential in the treatment of uveitis
by: Balevic SJ, et al.
Published: (2016-09-01)

The effectiveness of adalimumab treatment for non-infectious uveitis
by: Eiichi Hasegawa, et al.
Published: (2019-04-01)

Hidradenitis Suppurativa as a Paradoxical Side Effect to the Use of Adalimumab in Patients with Crohn’s Disease?
by: Beraldo RF, et al.
Published: (2020-08-01)

Long-Term Clinical Remission in Biologically Naïve Crohn’s Disease Patients with Adalimumab Therapy, Including Analyses of Switch from Adalimumab to Infliximab
by: Tsutomu Mizoshita, et al.
Published: (2016-06-01)

Adalimumab in the treatment of recurrent idiopathic bilateral nodular scleritis
by: Ahmed M Bawazeer, et al.
Published: (2011-01-01)

Two Cases of Paradoxical Hidradenitis Suppurativa while on Adalimumab
by: Glenn Harvin, et al.
Published: (2016-05-01)

Adalimumab versus infliximab in treating post-operative recurrence of Crohn's disease: a national cohort study
by: Carmen-Monica Preda, et al.

Crohn's-like disease in a patient with common variable immunodeficiency treated with azathioprine and adalimumab
by: Juan María Vázquez-Morón, et al.
Published: (2013-06-01)

Vitiligo during Treatment of Crohn’s Disease with Adalimumab: Adverse Effect or Co-Occurrence
by: Celia Posada, et al.
Published: (2011-02-01)

Efficacy of adalimumab for Crohn’s disease in real clinical practice
by: O V Knyazev, et al.
Published: (2017-02-01)

Determination of lower cut‐off levels of adalimumab associated with biochemical remission in Crohn's disease
by: Arne Carlsen, et al.
Published: (2020-06-01)

Résorption osseuse, ostéoclastogénèse et adalimumab : Projet BROCA (de l'original anglais : "Bone resorption, Osteoclastogenesis and Adalimumab")
by: Guay Bélanger, Sabrina
Published: (2015)